Press Releases

Press Releases

The information contained in press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.


18 September, 2020

CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis

18 September, 2020

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal

17 September, 2020

Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas

14 September, 2020

Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial

09 September, 2020

Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in the GVHD Community

02 September, 2020

Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM

01 September, 2020

Incyte to Present at Upcoming Investor Conference

18 August, 2020

National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas

04 August, 2020

Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

31 July, 2020

FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

of 1 2 3 4 5 Next page

For Media Inquiries

Catalina Loveman
Executive Director, Public Affairs

+1 302.498.6171 |

For Investor Relations

Michael Booth, D.Phil.
Divisional VP of Investor Relations and Corporate Responsibility

Phone: 302.498.5914


Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility

Phone: 302.498.6141


Christine Chiou
Senior Director, Investor Relations

Phone: 302.274.4773